Reframe Daily: All-oral myeloma combo works; stroke care simplified; 3 more breakthroughs

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A big stroke study found many people can use a blood thinner without adding aspirin and have less bleeding; a tiny nitroglycerin shot kept babies’ wrist arteries open for procedures; a simple three-pill combo helped people with hard-to-treat myeloma; a new drug that blocks IL-17 eased joint and skin symptoms; and a natural protein called transferrin protected the eye in early tests.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: Stroke patients who have both atrial fibrillation and artery narrowing may not need to add aspirin on top of a blood thinner—cutting bleeding risk without losing protection.

Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (practice-changing RCT using already-approved meds; doctors can apply now). 

Good news: A tiny under-the-skin dose of nitroglycerin before wrist artery catheter use helped keep the artery open in babies and toddlers.

Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Pediatric Patients: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂🙂 (simple technique with an approved drug; can be used now in hospitals). 

Good news: For relapsed myeloma, adding low-cost cyclophosphamide to pomalidomide + dexamethasone offers another proven, all-oral option.

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapsed or refractory myeloma (AMN003)

Market readiness: 🙂🙂🙂🙂 (phase 3 results with widely available drugs; clinicians can consider off-label while guidelines update). 

Good news: A new “nanobody” drug that blocks two IL-17 signals eased joint and skin symptoms in psoriatic arthritis in a placebo-controlled trial.

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Market readiness: 🙂🙂 (mid-stage clinical data; needs phase 3 and FDA review before use). 

Good news: Lab and animal studies show the natural iron-carrying protein transferrin can protect the retina—pointing to a possible treatment for dry AMD, where options are limited.

Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD)

Market readiness: 🙂 (preclinical; years of trials ahead before people can get it).

Thank you for taking the time to take care of yourself and your loved ones.